CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers

被引:39
|
作者
Jin, Chuan [1 ]
Ma, Jing [1 ]
Ramachandran, Mohanraj [1 ]
Yu, Di [1 ]
Essand, Magnus [1 ]
机构
[1] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden
基金
瑞典研究理事会;
关键词
NEUTROPHIL-ACTIVATING PROTEIN; CHIMERIC ANTIGEN RECEPTOR; IMMUNOTHERAPY; INFILTRATION; LYMPHOCYTES; EFFICACY; SURVIVAL; THERAPY;
D O I
10.1038/s41551-022-00875-5
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Chimeric antigen receptor T cells (CAR T cells) are effective against haematologic malignancies. However, in solid tumours, their potency is hampered by local immunosuppression and by the heterogeneous expression of the antigen that the CAR targets. Here we show that CAR T cells expressing a pluripotent pro-inflammatory neutrophil-activating protein (NAP) from Helicobacter pylori trigger endogenous bystander T-cell responses against solid cancers. In mice with subcutaneous murine pancreatic ductal adenocarcinomas, neuroblastomas or colon carcinomas, CAR(NAP) T cells led to slower tumour growth and higher survival rates than conventional mouse CAR T cells, regardless of target antigen, tumour type and host haplotype. In tumours with heterogeneous antigen expression, NAP secretion induced the formation of an immunologically 'hot' microenvironment that supported dendritic cell maturation and bystander responses, as indicated by epitope spreading and infiltration of cytotoxic CD8(+) T cells targeting tumour-associated antigens other than the CAR-targeted antigen. CAR T cells armed with NAP neither increased off-tumour toxicity nor hampered the efficacy of CAR T cells, and hence may have advantageous translational potential. T cells expressing a pluripotent pro-inflammatory neutrophil-activating protein from Helicobacter pylori trigger endogenous bystander T-cell responses against solid cancers.
引用
收藏
页码:830 / 841
页数:25
相关论文
共 50 条
  • [41] Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues (vol 3, pg 581, 2022)
    Feng, Zijie
    He, Xin
    Zhang, Xuyao
    Wu, Yuan
    Xing, Bowen
    Knowles, Alison
    Shan, Qiaonan
    Miller, Samuel
    Hojnacki, Taylor
    Ma, Jian
    Katona, Bryson W.
    Gade, Terence P. F.
    Siegel, Don L.
    Schrader, Jorg
    Metz, David C.
    June, Carl H.
    Hua, Xianxin
    NATURE CANCER, 2024, 5 (4) : 691 - 691
  • [42] Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
    Fischer-Riepe, Lena
    Kailayangiri, Sareetha
    Zimmermann, Katharina
    Pfeifer, Rita
    Aigner, Michael
    Altvater, Bianca
    Kretschmann, Sascha
    Voelkl, Simon
    Hartley, Jordan
    Dreger, Celine
    Petry, Katja
    Bosio, Andreas
    von Doellen, Angelika
    Hartmann, Wolfgang
    Lode, Holger
    Goerlich, Dennis
    Mackensen, Andreas
    Jungblut, Melanie
    Schambach, Axel
    Abken, Hinrich
    Rossig, Claudia
    CLINICAL CANCER RESEARCH, 2024, 30 (16) : 3564 - 3577
  • [43] A comparative study for mathematical modelling of the contest of CAR-T and tumour cells in solid cancers using fractional- and integer-order derivatives
    Kumar, Pushpendra
    Erturk, Vedat Suat
    JOURNAL OF ANALYSIS, 2024,
  • [44] Preclinical development of CAR T cells with antigen-inducible IL-18 enforcement to treat GD2-positive solid cancers
    Fischer-Riepe, Lena
    Kailayangiri, Sareetha
    Zimmermann, Katharina
    Pfeifer, Rita
    Aigner, Michael
    Altvater, Bianca
    Kretschmann, Sascha
    Voelkl, Simon
    Hartley, Jordan
    Dreger, Celine
    Petry, Katja
    Bosio, Andreas
    von Doellen, Angelika
    Hartmann, Wolfgang
    Lode, Holger
    Goerlich, Dennis
    Mackensen, Andreas
    Jungblut, Melanie
    Schambach, Axel
    Abken, Hinrich
    Rossig, Claudia
    CANCER RESEARCH, 2024, 84 (06)
  • [45] CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process
    Altvater, Bianca
    Kailayangiri, Sareetha
    Spurny, Christian
    Fluegge, Maike
    Meltzer, Jutta
    Greune, Lea
    Urban, Katja
    Schwoeppe, Christian
    Brand, Caroline
    Schliemann, Christoph
    Hintelmann, Heike
    Harrach, Saliha
    Hartmann, Wolfgang
    Abken, Hinrich
    Kuehle, Johannes
    Schambach, Axel
    Goerlich, Dennis
    Berdel, Wolfgang E.
    Rossig, Claudia
    CANCER GENE THERAPY, 2023, 30 (10) : 1355 - 1368
  • [46] CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process
    Bianca Altvater
    Sareetha Kailayangiri
    Christian Spurny
    Maike Flügge
    Jutta Meltzer
    Lea Greune
    Katja Urban
    Christian Schwöppe
    Caroline Brand
    Christoph Schliemann
    Heike Hintelmann
    Saliha Harrach
    Wolfgang Hartmann
    Hinrich Abken
    Johannes Kuehle
    Axel Schambach
    Dennis Görlich
    Wolfgang E. Berdel
    Claudia Rossig
    Cancer Gene Therapy, 2023, 30 : 1355 - 1368
  • [47] Antigen-Specific Regulatory T Cells Generated by Factor VIII-CAR Retroviruses Transduction Suppress Anti-Factor VIII Immune Responses
    Fu, Richard Y.
    Lyle, Meghan J.
    Cai, Xiaohe
    Khan, Iram
    Wang, Xuefeng
    Rawlings, David J.
    Miao, Carol H.
    MOLECULAR THERAPY, 2017, 25 (05) : 238 - 239
  • [48] Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis
    Guangyi Jiang
    Yu Yang Ng
    Johan C. K. Tay
    Zhicheng Du
    Lin Xiao
    Shu Wang
    Jianqing Zhu
    Cancer Immunology, Immunotherapy, 2023, 72 : 223 - 234
  • [49] Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer
    Ohta, Keisuke
    Sakoda, Yukimi
    Adachi, Keishi
    Shinozaki, Taro
    Nakajima, Masao
    Yasuda, Hiroyuki
    Nagano, Hiroaki
    Tamada, Koji
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (09): : 2514 - 2524
  • [50] Rapidly switchable universal CAR-T cells with improved safety profile allow for active targeting of PD-L1 expressing solid tumors
    Dietrich, Josephine
    Loff, Simon
    Spehr, Johannes
    Riewaldt, Julia
    Grunder, Cordula
    Schreiber, Maria
    Bachmann, Michael
    Ehninger, Gerhard
    Pehl, Michael
    Cartellieri, Marc
    Ehninger, Armin
    CANCER RESEARCH, 2020, 80 (16)